Keyword: Oxford BioMedica
Microsoft is bringing its coding skills to bear on biotech, with the goal of building a platform for programming the biology of living cells.
Axovant has clinical readouts from its switch into gene therapy after failed endeavors in Alzheimer’s—and the initial data look encouraging.
Boehringer will work with British academics and Oxford BioMedica to develop an inhaled, lentiviral vector-based gene therapy for cystic fibrosis.
Novartis has revealed the long-awaited interim Juliet data for its CAR-T candidate